Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
Resilience Raises $410m In US Government Funding
Executive Summary
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
You may also be interested in...
Viking’s Phase IIb NASH Data Provide Across-The-Board Success
Competing with Madrigal in the THRβ agonist class in non-alcoholic steatohepatitis, Viking’s VK2809 reports stronger efficacy and better safety and tolerability than resmetirom at that stage.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class
89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.